Researchers link the ability of the cells to bind and present DNA from pathogens and cell death to anemia, which is common in COVID-19, and immune activation.

Researchers report a new way of generating the cells from induced pluripotent stem cells in hopes they will one day be used in blood transfusions.

Two studies show that Plasmodium—the genus of protozoans that cause malaria—have an internal sense of time that synchronizes with their host’s circadian rhythms and allows the parasites to collectively attack blood cells.

Two clinical trial participants—one with β-thalassemia and one with sickle cell disease—appeared to benefit from the gene-editing treatments with minimal side effects, according to the companies.

James Herrick, a Chicago doctor, was the first to describe sickled red blood cells in a patient of African descent.

Myosin proteins tug on the cell membrane, giving an erythrocyte its distinct shape.

What happens when myosin inside red blood cells can't do its job?

Optical engineers have developed a portable field microscope that could aid the diagnosis of diseased cells.

These fossilized red blood cells (right), found in an ancient, blood-engorged Amblyomma tick (left), likely belonged to primates.

Artemisinin targets multiple parasite proteins after being activated by the iron in heme cofactors.

A new study is rewriting 50 years of biological dogma by suggesting that mature blood cells develop much more rapidly from stem cells than previously thought.

Researchers report finding evidence of red blood cells and proteins in 75-million-year-old dinosaur fossils.

A microfluidic device can safely remove glycerol from thawed red blood cells in minutes, potentially making frozen blood more feasible for routine transfusions.

Researchers have developed fast-dissolving particles that may one day prevent organ damage or death by instantly infusing oxygen into the blood.

To protect themselves during malaria infections, mice can kill their own healthy red blood cells, cutting off the parasite’s primary resource.

Amgen’s incomplete report on an early major trial of epoetin misled the medical community about the anemia drug’s risks and benefits—and helped make Amgen rich.